Target
N-formyl peptide receptor 2
Ligand
BDBM50238899
Substrate
n/a
Meas. Tech.
ChEMBL_1664517 (CHEMBL4014198)
IC50
13±n/a nM
Citation
 Skovbakke, SLSkovbakke, SLSkovbakke, SLHoldfeldt, AHoldfeldt, AHoldfeldt, ANielsen, CNielsen, CNielsen, CHansen, AMHansen, AMHansen, AMPerez-Gassol, IPerez-Gassol, IPerez-Gassol, IDahlgren, CDahlgren, CDahlgren, CForsman, HForsman, HForsman, HFranzyk, HFranzyk, HFranzyk, H Combining Elements from Two Antagonists of Formyl Peptide Receptor 2 Generates More Potent Peptidomimetic Antagonists. J Med Chem 60:6991-6997 (2017) [PubMed]  Article 
Target
Name:
N-formyl peptide receptor 2
Synonyms:
ALXR, FPRL1, FPR2 | FMLP-related receptor I FMLP-R-I | FPR2 | FPR2_HUMAN | FPRH1 | FPRL1 | Formyl Peptide Receptor-Like 1 | HM63 | LXA4 receptor | LXA4R | Lipoxin A4 receptor | Lipoxin A4 receptor (LXA4) | RFP | hFPRL
Type:
G Protein-Coupled Receptor (GPCR)
Mol. Mass.:
38968.35
Organism:
Homo sapiens (Human)
Description:
P25090
Residue:
351
Sequence:
METNFSTPLNEYEEVSYESAGYTVLRILPLVVLGVTFVLGVLGNGLVIWVAGFRMTRTVTTICYLNLALADFSFTATLPFLIVSMAMGEKWPFGWFLCKLIHIVVDINLFGSVFLIGFIALDRCICVLHPVWAQNHRTVSLAMKVIVGPWILALVLTLPVFLFLTTVTIPNGDTYCTFNFASWGGTPEERLKVAITMLTARGIIRFVIGFSLPMSIVAICYGLIAAKIHKKGMIKSSRPLRVLTAVVASFFICWFPFQLVALLGTVWLKEMLFYGKYKIIDILVNPTSSLAFFNSCLNPMLYVFVGQDFRERLIHSLPTSLERALSEDSAPTNDTAANSASPPAETELQAM
  
Inhibitor
Name:
BDBM50238899
Synonyms:
CHEMBL4066521
Type:
Small organic molecule
Emp. Form.:
C92H124N15O10
Mol. Mass.:
1600.0629
SMILES:
CCN(CC)c1ccc2c(-c3ccccc3C(=O)N[C@@H](CCCCN)C(=O)N(CCC(=O)N[C@@H](CCCCN)C(=O)N(CCC(=O)N[C@@H](CCCCN)C(=O)N(CCC(=O)N[C@@H](CCCCN)C(=O)N(CCC(N)=O)Cc3ccccc3)Cc3ccccc3)Cc3ccccc3)Cc3ccccc3)c3ccc(cc3oc2c1)=[N+](CC)CC |r,wU:33.34,47.48,61.62,wD:19.20,(17.07,-33.47,;15.74,-32.7,;15.74,-31.16,;17.07,-30.39,;18.39,-31.16,;14.39,-30.39,;14.38,-28.86,;13.06,-28.1,;11.73,-28.87,;10.39,-28.1,;10.39,-26.04,;9.04,-25.29,;9.04,-23.75,;10.37,-22.97,;11.7,-23.74,;11.7,-25.27,;13.03,-26.04,;13.03,-27.6,;14.39,-25.27,;15.74,-26.04,;15.74,-27.6,;17.07,-28.36,;17.07,-29.9,;18.4,-30.67,;19.73,-29.9,;17.08,-25.27,;17.08,-23.71,;18.42,-26.04,;18.43,-27.58,;19.76,-28.34,;21.09,-27.57,;21.09,-26.03,;22.43,-28.34,;23.75,-27.57,;23.76,-26.02,;25.09,-25.26,;25.08,-23.71,;26.41,-22.94,;26.41,-21.4,;25.09,-28.33,;25.1,-29.86,;26.42,-27.55,;27.75,-28.33,;27.76,-29.86,;29.1,-30.62,;30.43,-29.85,;29.1,-32.16,;30.43,-32.93,;31.76,-32.16,;33.1,-32.92,;34.43,-32.15,;35.76,-32.92,;37.09,-32.14,;30.44,-34.47,;29.11,-35.24,;31.77,-35.23,;31.78,-36.77,;30.44,-37.55,;30.45,-39.08,;31.78,-39.84,;29.12,-39.86,;29.12,-41.4,;30.46,-42.17,;30.46,-43.71,;31.8,-44.48,;33.13,-43.7,;34.47,-44.47,;27.79,-42.17,;26.45,-41.4,;27.79,-43.71,;29.13,-44.48,;29.13,-46.03,;27.8,-46.8,;27.8,-48.34,;26.46,-46.03,;26.46,-44.49,;25.12,-43.72,;25.12,-42.18,;23.79,-41.41,;22.45,-42.18,;22.46,-43.74,;23.8,-44.5,;33.1,-34.46,;34.43,-35.23,;34.43,-36.76,;35.77,-37.53,;37.1,-36.76,;37.09,-35.21,;35.76,-34.45,;26.42,-26.02,;27.75,-25.25,;29.08,-26.01,;30.41,-25.24,;30.41,-23.7,;29.06,-22.94,;27.74,-23.71,;19.76,-25.27,;19.75,-23.73,;21.09,-22.97,;21.08,-21.42,;19.74,-20.66,;18.41,-21.44,;18.42,-22.97,;9.06,-28.89,;7.73,-28.13,;6.41,-28.91,;6.43,-30.45,;7.75,-31.21,;9.07,-30.43,;10.42,-31.19,;11.74,-30.41,;13.08,-31.18,;5.08,-31.22,;3.74,-30.45,;2.41,-31.22,;5.08,-32.75,;3.74,-33.52,)|
Structure:
Search PDB for entries with ligand similarity: